{
  "version": 1,
  "updatedAt": "2025-01-20T00:00:00Z",
  "id": "lower-respiratory",
  "name": "Lower Respiratory Infections",
  "description": "Pneumonia, bronchitis, and lower airway infections",
  "icon": "air",
  "color": "#2196F3",
  "conditions": [
    {
      "id": "CAP",
      "name": "Community-Acquired Pneumonia (CAP)",
      "synonyms": [
        "CAP",
        "pneumonia",
        "lung infection"
      ],
      "icd10": [
        "J18.9",
        "J15.9"
      ],
      "severity": [
        "mild",
        "moderate",
        "severe"
      ],
      "shortDescription": "Acute infection of the pulmonary parenchyma acquired outside the hospital",
      "sections": {
        "overview": {
          "id": "overview",
          "title": "Overview & Clinical Presentation",
          "content": {
            "clinical_presentation": "Fever, cough (productive OR non-productive), dyspnea, pleuritic chest pain, tachypnea, hypoxemia. Physical exam may reveal crackles, bronchial breath sounds, OR dullness to percussion.",
            "diagnostic_criteria": "Clinical symptoms + radiographic infiltrate (chest X-ray OR CT) + exclusion of alternative diagnoses.",
            "red_flags": [
              "Hypotension (SBP <90 mmHg)",
              "Respiratory failure requiring mechanical ventilation",
              "Altered mental status",
              "Multilobar infiltrates",
              "Septic shock"
            ]
          },
          "references": []
        },
        "diagnostics": {
          "id": "diagnostics",
          "title": "Diagnostic Strategy & Tests",
          "content": {
            "when_to_test": "All patients with suspected CAP should have chest imaging. Blood cultures and sputum cultures recommended for hospitalized patients, especially those with severe CAP OR risk factors for MDRO.",
            "essential_tests": [
              "Chest X-ray (PA and lateral)",
              "Pulse oximetry OR ABG",
              "CBC with differential",
              "Basic metabolic panel",
              "Blood cultures (2 sets) before antibiotics"
            ],
            "conditional_tests": [
              "Sputum Gram stain and culture (if productive cough)",
              "Urinary antigen tests (Legionella, Pneumococcus)",
              "Respiratory viral panel (influenza season)",
              "CT chest (if X-ray inconclusive)"
            ],
            "turnaround_time": "Blood cultures: 24-48 hours. Urinary antigens: 1-2 hours. Respiratory PCR: 1-4 hours."
          },
          "references": []
        },
        "microbiology": {
          "id": "microbiology",
          "title": "Microbiology",
          "content": {
            "likely_pathogens": [
              "Streptococcus pneumoniae (30-40% of cases)",
              "Haemophilus influenzae (10-20%, more common in COPD)",
              "Mycoplasma pneumoniae (10-20%, younger patients)",
              "Chlamydophila pneumoniae (5-10%)",
              "Legionella pneumophila (2-8%, travel/water exposure)",
              "Respiratory viruses (influenza, RSV, SARS-CoV-2, 20-30%)"
            ],
            "resistance_patterns": "Macrolide resistance in S. pneumoniae: 20-40% in some regions. Penicillin resistance: 30-40% (but cephalosporins remain effective for pneumonia). H. influenzae: 30-40% produce beta-lactamase.",
            "mdro_risk_factors": [
              "Recent hospitalization within 90 days",
              "Recent antibiotic use within 90 days (any class)",
              "Chronic hemodialysis",
              "Immunosuppression (HIV, transplant, chemotherapy)",
              "Structural lung disease (bronchiectasis, COPD)"
            ],
            "resistance_considerations": {
              "global_trends": "MRSA prevalence declining in many regions (10-20% of S. aureus isolates). ESBL-producing Enterobacterales increasing in healthcare-associated pneumonia.",
              "high_risk_populations": "Prior antibiotics within 90 days significantly increases resistance risk across all pathogen classes."
            }
          },
          "references": []
        },
        "empiric": {
          "id": "empiric",
          "title": "Empiric Therapy",
          "content": {
            "first_line": {
              "mild_outpatient": "Amoxicillin 1g PO TID OR Doxycycline 100mg PO BID",
              "moderate_outpatient": "Amoxicillin-clavulanate 875mg PO BID + Azithromycin 500mg PO x1, then 250mg daily",
              "severe_hospitalized": "Ceftriaxone 1-2g IV daily + Azithromycin 500mg IV daily OR Levofloxacin 750mg IV daily"
            },
            "alternatives": "Beta-lactam allergy: Levofloxacin OR moxifloxacin monotherapy",
            "avoid_list": "Avoid fluoroquinolones if recent use (90 days) OR high local resistance"
          },
          "references": []
        },
        "definitive": {
          "id": "definitive",
          "title": "Definitive (Targeted) Therapy",
          "content": {
            "pathogen_specific_dosing": {
              "streptococcus_pneumoniae": {
                "penicillin_susceptible": {
                  "first_line": "Penicillin G 2-4 million units IV q4h OR Amoxicillin 1g PO q8h",
                  "alternative": "Ceftriaxone 1g IV q24h",
                  "duration": "5-7 days (minimum 5 days afebrile)"
                },
                "penicillin_resistant": {
                  "mic_4_to_8": "Ceftriaxone 2g IV q24h OR Levofloxacin 750mg IV/PO q24h",
                  "mic_greater_than_8": "Vancomycin 15-20mg/kg IV q8-12h OR Linezolid 600mg IV/PO q12h",
                  "note": "Penicillin resistance does NOT predict cephalosporin resistance for pneumonia"
                }
              },
              "haemophilus_influenzae": {
                "beta_lactamase_negative": "Ampicillin 2g IV q6h",
                "beta_lactamase_positive": "Amoxicillin-clavulanate 875mg PO q12h OR Ceftriaxone 1g IV q24h",
                "note": "30-40% produce beta-lactamase"
              },
              "legionella": {
                "first_line": "Levofloxacin 750mg IV/PO q24h OR Azithromycin 500mg IV/PO q24h",
                "duration": "7-10 days (immunocompetent), 14-21 days (immunocompromised)",
                "note": "Fluoroquinolones preferred over macrolides for severe disease"
              },
              "MRSA": {
                "first_line": "Vancomycin 15-20mg/kg IV q8-12h (target trough 15-20 mcg/mL)",
                "alternative": "Linezolid 600mg IV/PO q12h",
                "duration": "7-14 days (minimum 7 days after last positive culture)",
                "note": "Consider necrotizing pneumonia - may need longer duration"
              },
              "pseudomonas_aeruginosa": {
                "first_line": "Piperacillin-tazobactam 4.5g IV q6h OR Cefepime 2g IV q8h",
                "severe": "Add aminoglycoside (tobramycin 5-7mg/kg IV q24h) for first 3-5 days",
                "duration": "14 days (minimum)",
                "note": "Always obtain susceptibilities - resistance common"
              }
            },
            "pathogen_specific": {
              "S_pneumoniae": "See pathogen-specific dosing table above",
              "H_influenzae": "See pathogen-specific dosing table above",
              "Legionella": "See pathogen-specific dosing table above"
            },
            "de_escalation": "Switch to narrow-spectrum oral therapy once clinically stable and pathogen identified",
            "IV_to_po_switch": "Criteria: Afebrile >24h, hemodynamically stable, improving symptoms, able to take PO"
          },
          "references": []
        },
        "duration": {
          "id": "duration",
          "title": "Duration of Therapy",
          "content": {
            "standard": "5-7 days for most cases",
            "short_course": "5 days if clinically stable and afebrile",
            "prolonged": "7-14 days for severe CAP, bacteremia, OR complications (empyema, abscess)",
            "biomarker_guided_therapy": {
              "procalcitonin": {
                "initiation": "<0.25 ng/mL: consider withholding antibiotics (low probability of bacterial infection)",
                "stopping": "Decrease >80% from peak OR <0.25 ng/mL: safe to stop antibiotics",
                "evidence": "Reduces antibiotic duration by 2-3 days without increasing mortality (multiple RCTs)",
                "limitations": "Not validated in immunocompromised, not widely available"
              },
              "CRP": {
                "stopping": "Decrease >50% from peak suggests clinical response",
                "note": "Less specific than procalcitonin, but more widely available"
              }
            }
          },
          "references": []
        },
        "special": {
          "id": "special",
          "title": "Special Considerations",
          "content": {
            "renal_dose": "Adjust beta-lactams and fluoroquinolones for CrCl <30 mL/min",
            "pregnancy": "Preferred: Amoxicillin, ceftriaxone, azithromycin. Avoid: Fluoroquinolones, doxycycline",
            "obesity": "Consider higher doses of beta-lactams (e.g., ceftriaxone 2g daily)",
            "immunocompromised_patients": {
              "hiv_cd4_less_than_200": {
                "additional_pathogens": "PCP (Pneumocystis jirovecii), Cryptococcus, Mycobacterium avium complex",
                "empiric_coverage": "Add TMP-SMX 15-20mg/kg/day (TMP component) IV divided q6-8h for PCP coverage",
                "diagnostic_tests": "Induced sputum OR bronchoscopy with BAL for PCP, fungal, mycobacterial cultures"
              },
              "neutropenia_less_than_500": {
                "additional_pathogens": "Aspergillus, Mucor, Pseudomonas, Stenotrophomonas",
                "empiric_coverage": "Broad-spectrum beta-lactam + aminoglycoside + voriconazole OR amphotericin B",
                "diagnostic_tests": "CT chest (halo sign, air crescent sign), serum galactomannan, BAL"
              },
              "solid_organ_transplant": {
                "timeline": "<1 month: nosocomial bacteria. 1-6 months: CMV, PCP, Aspergillus. >6 months: community pathogens",
                "prophylaxis": "TMP-SMX for PCP, valganciclovir for CMV (first 3-6 months)",
                "note": "Always consider drug interactions with immunosuppressants (tacrolimus, cyclosporine)"
              }
            },
            "drug_interactions": {
              "fluoroquinolones": {
                "black_box_warnings": [
                  "Tendon rupture (especially Achilles) - risk increased with age >60, corticosteroids, transplant",
                  "Peripheral neuropathy (may be irreversible)",
                  "CNS effects (seizures, confusion, psychosis)",
                  "Aortic aneurysm/dissection - avoid in patients with known aneurysm OR risk factors"
                ],
                "drug_interactions": [
                  "QTc prolongation: avoid with other QT-prolonging drugs (azithromycin, amiodarone)",
                  "Warfarin: increases INR - monitor closely",
                  "Antacids/iron: reduce absorption - separate by 2-4 hours"
                ],
                "when_to_avoid": "Reserve for Pseudomonas OR penicillin-allergic patients. NOT first-line for CAP."
              },
              "macrolides": {
                "qtc_prolongation": "Azithromycin can prolong QTc - avoid in patients with QTc >450ms OR on other QT drugs",
                "drug_interactions": [
                  "Warfarin: increases INR",
                  "Statins: increased risk of rhabdomyolysis (especially with clarithromycin)"
                ]
              },
              "vancomycin": {
                "nephrotoxicity": "Monitor trough levels (target 15-20 mcg/mL for pneumonia). Avoid concurrent nephrotoxins (NSAIDs, aminoglycosides).",
                "red_man_syndrome": "Infuse over 60-90 minutes to prevent histamine release"
              }
            },
            "imaging_follow_up": {
              "routine_follow_up": "Chest X-ray at 6 weeks for all patients >50 years OR smokers (rule out underlying malignancy)",
              "early_follow_up": "Repeat CXR at 48-72h if: no clinical improvement, worsening symptoms, OR concern for complications",
              "ct_indications": [
                "Failure to improve after 72h of appropriate antibiotics",
                "Suspected empyema OR lung abscess",
                "Recurrent pneumonia in same location (rule out obstruction)",
                "Immunocompromised (evaluate for fungal/atypical infections)"
              ],
              "resolution_time": "Radiographic resolution lags clinical improvement: 4-6 weeks for young patients, 12 weeks for elderly/COPD"
            },
            "clinical_pearls": [
              "Sputum Gram stain is underutilized - can guide early therapy if quality specimen (>25 PMNs, <10 epithelial cells per LPF)",
              "Procalcitonin <0.25 ng/mL has 90% NPV for bacterial pneumonia - consider stopping antibiotics",
              "Parapneumonic effusion in 40% of CAP - tap if >1cm on lateral decubitus film",
              "Failure to improve by 72h: consider resistant organism, empyema, PE, OR non-infectious mimic",
              "POst-obstructive pneumonia: always follow-up CXR at 6 weeks to rule out underlying malignancy",
              "CURB-65 score ≥2 OR PSI class IV-V: consider hospitalization",
              "Legionella: think of travel, water exposure, hyponatremia, elevated LFTS"
            ]
          },
          "references": []
        },
        "stewardship": {
          "id": "stewardship",
          "title": "Stewardship & Diagnostic Alerts",
          "content": {
            "avoid_unnecessary_cultures": "Outpatient CAP: Cultures not routinely needed",
            "timeout_checklist": [
              "Review culture results at 48-72 hours",
              "De-escalate to narrow-spectrum therapy",
              "Switch IV to PO when appropriate",
              "Reassess duration (avoid >7 days unless complicated)"
            ],
            "IV_to_po_opportunities": "Most patients can switch to PO by day 2-3 if clinically stable"
          },
          "references": []
        },
        "references": {
          "id": "references",
          "title": "References",
          "content": {},
          "references": [
            {
              "label": "IDSA/ATS Community-Acquired Pneumonia Guidelines (2019)",
              "url": "https://www.idsociety.org/practice-guideline/community-acquired-pneumonia-CAP-in-adults/"
            },
            {
              "label": "Sanford Guide to Antimicrobial Therapy (2025)",
              "url": "https://www.sanfordguide.com/"
            },
            {
              "label": "WHO Guidelines for Management of Pneumonia",
              "url": "https://www.WHO.int/teams/integrated-health-services/clinical-services-and-systems/surgical-care/pneumonia"
            }
          ]
        }
      }
    },
    {
      "id": "HAP-VAP",
      "name": "Hospital-Acquired Pneumonia (HAP) / Ventilator-Associated Pneumonia (VAP)",
      "synonyms": [
        "HAP",
        "VAP",
        "nosocomial pneumonia"
      ],
      "icd10": [
        "J18.9",
        "J95.851"
      ],
      "severity": [
        "moderate",
        "severe"
      ],
      "shortDescription": "Pneumonia occurring ≥48 hours after hospital admission OR intubation",
      "sections": {
        "overview": {
          "id": "overview",
          "title": "Overview & Clinical Presentation",
          "content": {
            "clinical_presentation": "New OR progressive infiltrate on chest imaging + clinical signs (fever, leukocytosis, purulent sputum, hypoxemia)",
            "diagnostic_criteria": "HAP: ≥48h after admission. VAP: ≥48h after intubation. Clinical + radiographic evidence.",
            "red_flags": [
              "Septic shock",
              "Rapid progression",
              "Multidrug-resistant organisms",
              "Immunosuppression"
            ]
          },
          "references": []
        },
        "diagnostics": {
          "id": "diagnostics",
          "title": "Diagnostic Strategy & Tests",
          "content": {
            "when_to_test": "All patients: Obtain lower respiratory tract cultures before starting antibiotics",
            "essential_tests": [
              "Chest X-ray OR CT",
              "Blood cultures (2 sets)",
              "Respiratory culture (endotracheal aspirate OR BAL)",
              "CBC, CMP"
            ],
            "conditional_tests": [
              "MRSA nasal PCR (negative predictive value for MRSA pneumonia)",
              "Respiratory viral panel",
              "Fungal cultures (if immunocompromised)"
            ],
            "turnaround_time": "Cultures: 48-72 hours. MRSA PCR: 1-2 hours."
          },
          "references": []
        },
        "microbiology": {
          "id": "microbiology",
          "title": "Microbiology",
          "content": {
            "likely_pathogens": [
              "Pseudomonas aeruginosa (20-30% of HAP/VAP)",
              "MRSA (15-30% in ICUs)",
              "Klebsiella pneumoniae (10-20%, ESBL common)",
              "Acinetobacter baumannii (5-15%, often MDR)",
              "Enterobacter spp. (5-10%, AmpC resistance)",
              "Stenotrophomonas maltophilia (5%, intrinsically resistant)"
            ],
            "resistance_patterns": "High rates of ESBL (20-40%), carbapenem resistance (5-20%), and MRSA (15-30%) in ICUs. Pseudomonas: 20-30% resistant to cefepime/piperacillin-tazobactam.",
            "mdro_risk_factors": [
              "Prior IV antibiotics within 90 days (strongest predictor)",
              "≥5 days hospitalization before pneumonia onset",
              "Septic shock at presentation",
              "ARDS requiring mechanical ventilation",
              "Renal replacement therapy (hemodialysis/CRRT)"
            ],
            "resistance_considerations": {
              "global_trends": "Carbapenem-resistant Enterobacterales (CRE) increasing globally (5-20% in some regions). Extensively drug-resistant (XDR) Pseudomonas and Acinetobacter emerging.",
              "high_risk_populations": "ICU patients with prolonged hospitalization (>7 days) and multiple antibiotic courses have 50-70% risk of MDRO."
            }
          },
          "references": []
        },
        "empiric": {
          "id": "empiric",
          "title": "Empiric Therapy",
          "content": {
            "first_line": {
              "no_mdro_risk": "Piperacillin-tazobactam 4.5g IV q6h OR Cefepime 2g IV q8h OR Meropenem 1g IV q8h",
              "mdro_risk": "Antipseudomonal beta-lactam (pip-tazo, cefepime, OR meropenem) + Vancomycin 15-20mg/kg IV q8-12h OR Linezolid 600mg IV q12h"
            },
            "alternatives": "If carbapenem-resistant: Ceftazidime-avibactam, meropenem-vaborbactam, OR polymyxin-based regimen",
            "avoid_list": "Avoid monotherapy in severe HAP/VAP with MDRO risk"
          },
          "references": []
        },
        "definitive": {
          "id": "definitive",
          "title": "Definitive (Targeted) Therapy",
          "content": {
            "pathogen_specific_dosing": {
              "MRSA": {
                "first_line": "Vancomycin 15-20mg/kg IV q8-12h (target trough 15-20 mcg/mL for pneumonia)",
                "alternative": "Linezolid 600mg IV/PO q12h (preferred if vancomycin MIC ≥1.5 OR renal dysfunction)",
                "duration": "7-14 days (minimum 7 days after clinical stability)",
                "note": "Linezolid has better lung penetration than vancomycin; consider for severe VAP"
              },
              "pseudomonas_aeruginosa": {
                "first_line": "Cefepime 2g IV q8h OR Piperacillin-tazobactam 4.5g IV q6h (based on susceptibility)",
                "alternative": "Meropenem 1g IV q8h OR Aztreonam 2g IV q8h (if beta-lactam allergy)",
                "severe": "Consider combination therapy (beta-lactam + aminoglycoside OR fluoroquinolone) for first 3-5 days",
                "duration": "14 days (minimum)",
                "note": "Always check susceptibilities - resistance rates 20-30% for cefepime/pip-tazo"
              },
              "esbl_klebsiella": {
                "first_line": "Meropenem 1g IV q8h OR Ertapenem 1g IV q24h (if not Pseudomonas)",
                "alternative": "Ceftazidime-avibactam 2.5g IV q8h (if carbapenem-sparing desired)",
                "duration": "7-14 days",
                "note": "Avoid cephalosporins and piperacillin-tazobactam even if susceptible in vitro"
              },
              "cre_carbapenem_resistant": {
                "first_line": "Ceftazidime-avibactam 2.5g IV q8h OR Meropenem-vaborbactam 4g IV q8h",
                "alternative": "Polymyxin B 2.5mg/kg loading, then 1.5mg/kg q12h + Tigecycline 100mg loading, then 50mg q12h",
                "duration": "14-21 days",
                "note": "Consult infectious disease specialist. Consider combination therapy for severe infections."
              },
              "acinetobacter_baumannii": {
                "first_line": "Ampicillin-sulbactam 3g IV q6h (if susceptible) OR Polymyxin B-based regimen",
                "alternative": "Tigecycline 100mg loading, then 50mg IV q12h + Carbapenem (if susceptible)",
                "duration": "14-21 days",
                "note": "Often XDR - consult ID. Inhaled colistin may be adjunctive therapy."
              }
            },
            "pathogen_specific": {
              "MRSA": "See pathogen-specific dosing table above",
              "Pseudomonas": "See pathogen-specific dosing table above",
              "ESBL_Klebsiella": "See pathogen-specific dosing table above",
              "CRE": "See pathogen-specific dosing table above"
            },
            "de_escalation": "Narrow to single agent once pathogen identified and susceptibilities known. Stop MRSA coverage if cultures negative and MRSA nasal PCR negative.",
            "IV_to_po_switch": "Limited PO options for HAP/VAP; most require full IV course. Linezolid and fluoroquinolones have excellent bioavailability if PO switch needed."
          },
          "references": []
        },
        "duration": {
          "id": "duration",
          "title": "Duration of Therapy",
          "content": {
            "standard": "7 days for most cases",
            "short_course": "7 days if good clinical response and susceptible pathogen",
            "prolonged": "14 days for non-fermenting GNRs (Pseudomonas, Acinetobacter), MRSA with bacteremia, OR slow clinical response",
            "biomarker_guided_therapy": {
              "procalcitonin": {
                "stopping": "Decrease >80% from peak OR <0.5 ng/mL: consider stopping antibiotics at day 7",
                "evidence": "Safe to shorten duration in HAP/VAP with good clinical response (multiple RCTs)",
                "limitations": "Not validated for MDRO infections OR immunocompromised patients"
              },
              "clinical_stability_criteria": {
                "criteria": [
                  "Afebrile >48 hours",
                  "Hemodynamically stable (no vasopressors)",
                  "Improving oxygenation (PaO2/FiO2 ratio improving)",
                  "Decreasing WBC and inflammatory markers"
                ],
                "note": "If all criteria met at day 7, consider stopping antibiotics (even if radiographic improvement incomplete)"
              }
            }
          },
          "references": []
        },
        "special": {
          "id": "special",
          "title": "Special Considerations",
          "content": {
            "renal_dose": "Adjust all beta-lactams, vancomycin, and aminoglycosides for renal function. Use CRRT dosing if on continuous renal replacement therapy.",
            "obesity": "Use actual body weight for vancomycin loading dose (25-30mg/kg); consider extended infusion beta-lactams (cefepime 2g over 4h, pip-tazo 4.5g over 4h)",
            "immunocompromised": "Consider fungal coverage (voriconazole, amphotericin B) if risk factors present (neutropenia, transplant, prolonged corticosteroids)",
            "drug_interactions": {
              "vancomycin": {
                "nephrotoxicity": "Monitor trough levels q3-4 days. Target 15-20 mcg/mL for pneumonia. Avoid concurrent nephrotoxins (aminoglycosides, NSAIDs, contrast).",
                "red_man_syndrome": "Infuse over 90-120 minutes (1g/hour max rate)"
              },
              "linezolid": {
                "serotonin_syndrome": "Avoid with SSRIs, SNRIs, MAOIs. Risk of serotonin syndrome.",
                "myelosuppression": "Monitor CBC weekly. Thrombocytopenia and anemia common after 2 weeks.",
                "note": "No renal dose adjustment needed - advantage in renal failure"
              },
              "Polymyxins": {
                "nephrotoxicity": "Occurs in 30-60% of patients. Monitor SCr daily. Avoid other nephrotoxins.",
                "neurotoxicity": "Paresthesias, dizziness, ataxia. Reduce dose in renal dysfunction."
              }
            },
            "clinical_pearls": [
              "MRSA nasal PCR negative has 95% NPV for MRSA pneumonia - stop empiric MRSA coverage if negative",
              "Endotracheal aspirate (ETA) is non-inferior to BAL for diagnosis - less invasive",
              "Ventilator bundle reduces VAP: HOB elevation, daily sedation vacation, oral care with chlorhexidine",
              "Failure to improve by day 3: consider resistant organism, empyema, OR non-infectious mimic (ARDS, PE, CHF)",
              "Double Pseudomonas coverage (beta-lactam + aminoglycoside/fluoroquinolone) does NOT improve outcomes - use monotherapy once susceptible",
              "Acinetobacter and Stenotrophomonas: often XDR - consult ID early"
            ]
          },
          "references": []
        },
        "stewardship": {
          "id": "stewardship",
          "title": "Stewardship & Diagnostic Alerts",
          "content": {
            "timeout_checklist": [
              "Review cultures at 48-72 hours",
              "De-escalate MRSA coverage if cultures negative and MRSA PCR negative",
              "De-escalate to monotherapy if single pathogen identified",
              "Reassess duration at day 7"
            ],
            "IV_to_po_opportunities": "Limited; most HAP/VAP requires full IV course"
          },
          "references": []
        },
        "references": {
          "id": "references",
          "title": "References",
          "content": {},
          "references": [
            {
              "label": "IDSA/ATS Hospital-Acquired and Ventilator-Associated Pneumonia Guidelines (2016)",
              "url": "https://www.idsociety.org/practice-guideline/hospital-acquired-and-ventilator-associated-pneumonia/"
            },
            {
              "label": "CDC HAI Prevention Guidelines",
              "url": "https://www.CDC.gov/hai/prevent/prevent_pubs.html"
            },
            {
              "label": "Sanford Guide to Antimicrobial Therapy (2025)",
              "url": "https://www.sanfordguide.com/"
            }
          ]
        }
      }
    },
    {
      "id": "HCAP",
      "name": "Healthcare-Associated Pneumonia (HCAP)",
      "synonyms": [
        "HCAP",
        "healthcare pneumonia",
        "nursing home pneumonia"
      ],
      "icd10": [
        "J18.9",
        "J15.9"
      ],
      "severity": [
        "moderate",
        "severe"
      ],
      "shortDescription": "Pneumonia in patients with recent healthcare exposure (nursing home, dialysis, home infusion, hospitalization within 90 days)",
      "sections": {
        "overview": {
          "id": "overview",
          "title": "Overview & Clinical Presentation",
          "content": {
            "definition": "Pneumonia occurring in patients with recent healthcare contact: nursing home residents, hospitalization within 90 days, home infusion therapy, chronic dialysis within 30 days, OR immunosuppression.",
            "clinical_presentation": "Similar to CAP: fever, cough, dyspnea, pleuritic chest pain. Higher risk of multidrug-resistant organisms (MDRO) compared to CAP.",
            "risk_factors": [
              "Nursing home residence",
              "Hospitalization within 90 days",
              "Chronic hemodialysis",
              "Home wound care OR IV therapy",
              "Immunosuppression (chemotherapy, steroids)",
              "Prior antibiotic use within 90 days"
            ],
            "note": "The HCAP designation was removed from 2016 IDSA/ATS HAP/VAP guidelines due to poor predictive value for MDRO. Current approach: individualized risk assessment for MDRO rather than blanket HCAP category."
          },
          "references": []
        },
        "diagnostics": {
          "id": "diagnostics",
          "title": "Diagnostic Strategy & Tests",
          "content": {
            "essential_tests": [
              "Chest X-ray (PA and lateral)",
              "Pulse oximetry OR ABG",
              "CBC with differential",
              "Basic metabolic panel",
              "Blood cultures (2 sets) before antibiotics",
              "Sputum Gram stain and culture (high yield for MDRO)"
            ],
            "conditional_tests": [
              "Respiratory viral panel (influenza season)",
              "Urinary antigen tests (Legionella, Pneumococcus)",
              "CT chest (if X-ray inconclusive)",
              "Procalcitonin (to guide antibiotic duration)"
            ],
            "severity_assessment": "Use CURB-65 OR PSI to determine admission need. Consider ICU admission for severe sepsis, respiratory failure, OR hemodynamic instability."
          },
          "references": []
        },
        "microbiology": {
          "id": "microbiology",
          "title": "Microbiology & Pathogens",
          "content": {
            "common_pathogens": [
              "Streptococcus pneumoniae (most common)",
              "Haemophilus influenzae",
              "Staphylococcus aureus (including MRSA)",
              "Gram-negative bacilli (E. coli, Klebsiella, Pseudomonas aeruginosa)",
              "Anaerobes (if aspiration risk)"
            ],
            "mdro_risk_factors": [
              "Prior IV antibiotics within 90 days",
              "Prior MDRO colonization OR infection",
              "Hospitalization ≥5 days in past 90 days",
              "High local MDRO prevalence (>10-20%)"
            ],
            "resistance_patterns": "MRSA prevalence 10-30% in HCAP. Pseudomonas risk increased with structural lung disease (bronchiectasis, COPD) OR prior fluoroquinolone use."
          },
          "references": []
        },
        "empiric": {
          "id": "empiric",
          "title": "Empiric Antibiotic Therapy",
          "content": {
            "low_mdro_risk": {
              "regimen": "Treat as CAP (see CAP module)",
              "options": [
                "Ceftriaxone 1-2g IV q24h + Azithromycin 500mg IV/PO q24h",
                "Levofloxacin 750mg IV/PO q24h (monotherapy)",
                "Ceftriaxone 1-2g IV q24h + Doxycycline 100mg PO q12h"
              ]
            },
            "high_mdro_risk": {
              "regimen": "Broad-spectrum coverage for MRSA + Pseudomonas",
              "options": [
                "Vancomycin 15-20mg/kg IV q8-12h (target trough 15-20) + Piperacillin-tazobactam 4.5g IV q6h",
                "Linezolid 600mg IV/PO q12h + Cefepime 2g IV q8h",
                "Vancomycin + Meropenem 1g IV q8h (if prior carbapenem-resistant organism)"
              ],
              "note": "Add azithromycin 500mg IV q24h if atypical coverage needed (Legionella risk)"
            },
            "de_escalation": "De-escalate based on culture results and clinical response within 48-72 hours. Discontinue MRSA coverage if MRSA-negative cultures and clinical improvement."
          },
          "references": []
        },
        "definitive": {
          "id": "definitive",
          "title": "Pathogen-Directed Therapy",
          "content": {
            "strep_pneumoniae": "Ceftriaxone 1-2g IV q24h OR Penicillin G 2-4 MU IV q4h (if susceptible)",
            "MRSA": "Vancomycin 15-20mg/kg IV q8-12h OR Linezolid 600mg IV/PO q12h",
            "pseudomonas": "Piperacillin-tazobactam 4.5g IV q6h OR Cefepime 2g IV q8h OR Meropenem 1g IV q8h",
            "h_influenzae": "Ceftriaxone 1-2g IV q24h OR Ampicillin-sulbactam 3g IV q6h",
            "klebsiella_esbl": "Meropenem 1g IV q8h OR Ertapenem 1g IV q24h",
            "IV_to_po_switch": "Switch to PO when: afebrile >24h, hemodynamically stable, improving clinically, able to take PO, functioning GI tract"
          },
          "references": []
        },
        "duration": {
          "id": "duration",
          "title": "Treatment Duration",
          "content": {
            "standard_duration": "5-7 days for most patients with good clinical response",
            "extended_duration": "7-14 days for: MRSA pneumonia, Pseudomonas pneumonia, bacteremic pneumonia, slow clinical response, immunocompromised",
            "stopping_criteria": [
              "Afebrile for 48-72 hours",
              "Hemodynamically stable",
              "Improving respiratory symptoms",
              "Able to take oral medications",
              "No evidence of metastatic infection"
            ],
            "procalcitonin_guided": "Consider procalcitonin-guided therapy: stop antibiotics when PCT <0.25 ng/mL OR decreased by 80% from peak"
          },
          "references": []
        },
        "special": {
          "id": "special",
          "title": "Special Populations",
          "content": {
            "renal_impairment": "Adjust doses for beta-lactams, vancomycin, fluoroquinolones. Avoid aminoglycosides if possible. Monitor vancomycin trough levels.",
            "hepatic_impairment": "Use caution with linezolid (risk of lactic acidosis). Avoid tigecycline in severe hepatic dysfunction.",
            "pregnancy": "Preferred: Ceftriaxone + Azithromycin. Avoid fluoroquinolones, doxycycline, aminoglycosides.",
            "immunocompromised": "Broader coverage needed. Consider fungal (Aspergillus, Pneumocystis) and viral (CMV) etiologies. Consult infectious disease specialist."
          },
          "references": []
        },
        "stewardship": {
          "id": "stewardship",
          "title": "Antimicrobial Stewardship",
          "content": {
            "red_flags": [
              "Empiric MRSA/Pseudomonas coverage without risk factors",
              "Continuation of broad-spectrum antibiotics beyond 48-72h without positive cultures",
              "Failure to de-escalate based on culture results",
              "Treatment duration >7 days without clear indication"
            ],
            "IV_to_po_criteria": [
              "Afebrile >24 hours",
              "Hemodynamically stable (HR <100, SBP >90)",
              "Improving respiratory symptoms",
              "Oxygen saturation >90% on room air OR baseline",
              "Able to take and absorb oral medications"
            ],
            "antibiotic_timeout": "Perform 48-72 hour review: Are cultures positive? Is patient improving? Can we narrow spectrum? Can we switch to PO? Can we stop antibiotics?"
          },
          "references": []
        },
        "references": {
          "id": "references",
          "title": "Clinical References",
          "content": {},
          "references": [
            {
              "label": "IDSA/ATS HAP/VAP Guidelines (2016) - HCAP Discussion",
              "url": "https://www.idsociety.org/practice-guideline/hospital-acquired-and-ventilator-associated-pneumonia/"
            },
            {
              "label": "Sanford Guide to Antimicrobial Therapy (2025)",
              "url": "https://www.sanfordguide.com/"
            }
          ]
        }
      }
    },
    {
      "id": "aspiration-pneumonia",
      "name": "Aspiration Pneumonia",
      "synonyms": [
        "aspiration pneumonia",
        "aspiration pneumonitis",
        "chemical pneumonitis"
      ],
      "icd10": [
        "J69.0",
        "J69.8"
      ],
      "severity": [
        "moderate",
        "severe"
      ],
      "shortDescription": "Pneumonia resulting from aspiration of oropharyngeal OR gastric contents into the lower respiratory tract",
      "sections": {
        "overview": {
          "id": "overview",
          "title": "Overview & Clinical Presentation",
          "content": {
            "definition": "Aspiration pneumonia: bacterial infection following aspiration of colonized oropharyngeal secretions. Aspiration pneumonitis: chemical injury from gastric acid (Mendelson syndrome) - does NOT require antibiotics.",
            "clinical_presentation": "Fever, cough (often productive with foul-smelling sputum), dyspnea, pleuritic chest pain. Infiltrates typically in dependent lung segments (right lower lobe, posterior segments).",
            "risk_factors": [
              "Dysphagia (stroke, dementia, Parkinson's)",
              "Altered mental status (sedation, alcohol, seizures)",
              "Gastroesophageal reflux disease (GERD)",
              "Mechanical ventilation OR tracheostomy",
              "POor oral hygiene",
              "Tube feeding",
              "Advanced age with frailty"
            ],
            "key_distinction": "Aspiration pneumonitis (chemical injury) presents acutely (<2h) with dyspnea, tachypnea, hypoxemia but NO fever initially. Aspiration pneumonia (bacterial infection) develops over 24-48h with fever and purulent sputum."
          },
          "references": []
        },
        "diagnostics": {
          "id": "diagnostics",
          "title": "Diagnostic Strategy & Tests",
          "content": {
            "essential_tests": [
              "Chest X-ray (look for infiltrates in dependent segments: RLL, posterior segments)",
              "Pulse oximetry OR ABG",
              "CBC with differential (leukocytosis suggests bacterial infection)",
              "Basic metabolic panel",
              "Blood cultures (if febrile OR septic)"
            ],
            "conditional_tests": [
              "Sputum Gram stain and culture (if productive cough)",
              "CT chest (if complicated by abscess OR empyema)",
              "Swallowing evaluation (speech pathology consult)",
              "Modified barium swallow OR FEES (fiberoptic endoscopic evaluation of swallowing)"
            ],
            "diagnostic_stewardship": "Do NOT treat aspiration pneumonitis (chemical injury) with antibiotics. Only treat if bacterial infection is suspected (fever, purulent sputum, leukocytosis, infiltrate persisting >48h)."
          },
          "references": []
        },
        "microbiology": {
          "id": "microbiology",
          "title": "Microbiology & Pathogens",
          "content": {
            "common_pathogens": [
              "Streptococcus pneumoniae",
              "Haemophilus influenzae",
              "Staphylococcus aureus",
              "Gram-negative bacilli (E. coli, Klebsiella, Enterobacter)",
              "Oral anaerobes (Peptostreptococcus, Prevotella, Bacteroides) - role controversial"
            ],
            "anaerobic_coverage_controversy": "Current evidence (2024) does NOT support routine anaerobic coverage. Anaerobes rarely isolated from aspiration pneumonia cultures. Reserve anaerobic coverage for lung abscess OR empyema.",
            "community_vs_healthcare": "Community-acquired aspiration: typical CAP pathogens. Healthcare-associated aspiration: higher risk of MRSA and Pseudomonas."
          },
          "references": []
        },
        "empiric": {
          "id": "empiric",
          "title": "Empiric Antibiotic Therapy",
          "content": {
            "community_acquired": {
              "regimen": "Treat as CAP - NO routine anaerobic coverage needed",
              "options": [
                "Ceftriaxone 1-2g IV q24h + Azithromycin 500mg IV/PO q24h",
                "Levofloxacin 750mg IV/PO q24h (monotherapy)",
                "Ampicillin-sulbactam 3g IV q6h (if mild, provides some anaerobic coverage)"
              ]
            },
            "healthcare_associated": {
              "regimen": "Broader coverage for MRSA/Pseudomonas if risk factors present",
              "options": [
                "Vancomycin 15-20mg/kg IV q8-12h + Piperacillin-tazobactam 4.5g IV q6h",
                "Linezolid 600mg IV/PO q12h + Cefepime 2g IV q8h"
              ]
            },
            "anaerobic_coverage_indications": {
              "when_to_add": "Only if: lung abscess, empyema, necrotizing pneumonia, OR putrid sputum",
              "options": [
                "Ampicillin-sulbactam 3g IV q6h",
                "Piperacillin-tazobactam 4.5g IV q6h",
                "Clindamycin 600-900mg IV q8h (add to beta-lactam)"
              ]
            },
            "note": "Avoid unnecessary anaerobic coverage (clindamycin, metronidazole) unless clear indication. Overuse contributes to C. difficile risk."
          },
          "references": []
        },
        "definitive": {
          "id": "definitive",
          "title": "Pathogen-Directed Therapy",
          "content": {
            "strep_pneumoniae": "Ceftriaxone 1-2g IV q24h OR Penicillin G 2-4 MU IV q4h",
            "MRSA": "Vancomycin 15-20mg/kg IV q8-12h OR Linezolid 600mg IV/PO q12h",
            "pseudomonas": "Piperacillin-tazobactam 4.5g IV q6h OR Cefepime 2g IV q8h",
            "anaerobes": "Ampicillin-sulbactam 3g IV q6h OR Clindamycin 600-900mg IV q8h",
            "de_escalation": "Narrow spectrum based on culture results. Discontinue anaerobic coverage if no abscess/empyema and clinical improvement.",
            "IV_to_po_switch": "Switch when clinically stable: Amoxicillin-clavulanate 875mg PO q12h OR Levofloxacin 750mg PO q24h"
          },
          "references": []
        },
        "duration": {
          "id": "duration",
          "title": "Treatment Duration",
          "content": {
            "standard_duration": "5-7 days for uncomplicated aspiration pneumonia with good clinical response",
            "extended_duration": "7-14 days for: complicated pneumonia, bacteremia, slow clinical response, immunocompromised",
            "lung_abscess": "3-4 weeks IV therapy, then switch to PO for total 6-8 weeks (see Lung Abscess module)",
            "stopping_criteria": [
              "Afebrile for 48-72 hours",
              "Hemodynamically stable",
              "Improving respiratory symptoms",
              "Able to take oral medications safely (swallowing evaluation)",
              "No evidence of abscess OR empyema"
            ]
          },
          "references": []
        },
        "special": {
          "id": "special",
          "title": "Special Populations & Prevention",
          "content": {
            "prevention_strategies": [
              "Swallowing evaluation and dysphagia management (reduces recurrence by 50%)",
              "Elevate head of bed 30-45 degrees during feeding and for 30-60 min after",
              "Oral hygiene (tooth brushing BID, chlorhexidine mouthwash) - reduces bacterial load",
              "Avoid sedatives and anticholinergics when possible",
              "Consider PEG tube if recurrent aspiration (controversial - does NOT prevent aspiration)",
              "Treat GERD if present (but PPIs may INCREASE aspiration risk by altering gastric pH)"
            ],
            "renal_impairment": "Adjust beta-lactam doses. Monitor vancomycin levels. Avoid aminoglycosides.",
            "pregnancy": "Preferred: Ampicillin-sulbactam OR Ceftriaxone + Azithromycin. Avoid fluoroquinolones.",
            "immunocompromised": "Consider broader coverage and longer duration. Rule out fungal (Aspergillus) OR viral (CMV) etiologies.",
            "clinical_pearls": [
              "Witnessed aspiration + infiltrate in dependent segment (RLL, posterior segments) = aspiration pneumonia",
              "Anaerobic coverage is OVERUSED - reserve for lung abscess OR empyema",
              "Swallowing evaluation reduces recurrent aspiration by 50%",
              "Proton pump inhibitors INCREASE aspiration pneumonia risk (alter gastric pH, promote bacterial overgrowth)",
              "Tube feeding does NOT prevent aspiration - consider post-pyloric feeding if recurrent",
              "Foul-smelling sputum suggests anaerobes - but still rare in aspiration pneumonia without abscess",
              "Aspiration pneumonitis (chemical injury) resolves in 48-72h without antibiotics - do NOT treat empirically"
            ]
          },
          "references": []
        },
        "stewardship": {
          "id": "stewardship",
          "title": "Antimicrobial Stewardship",
          "content": {
            "red_flags": [
              "Treating aspiration pneumonitis (chemical injury) with antibiotics - NOT indicated",
              "Routine anaerobic coverage without lung abscess OR empyema",
              "Prolonged antibiotic therapy (>7 days) without clear indication",
              "Failure to perform swallowing evaluation to prevent recurrence"
            ],
            "key_stewardship_points": [
              "Aspiration pneumonitis does NOT require antibiotics (supportive care only)",
              "Anaerobic coverage NOT routinely needed for aspiration pneumonia",
              "Treat as CAP unless healthcare-associated risk factors present",
              "Address underlying aspiration risk (dysphagia, GERD, oral hygiene)"
            ],
            "antibiotic_timeout": "48-72h review: Is this bacterial infection OR chemical pneumonitis? Are cultures positive? Can we narrow spectrum? Can we stop anaerobic coverage?"
          },
          "references": []
        },
        "references": {
          "id": "references",
          "title": "Clinical References",
          "content": {},
          "references": [
            {
              "label": "ATS/IDSA Aspiration Pneumonia Guidelines",
              "url": "https://www.thoracic.org/statements/resources/mtpi/aspiration-pneumonia.pdf"
            },
            {
              "label": "Sanford Guide to Antimicrobial Therapy (2025)",
              "url": "https://www.sanfordguide.com/"
            },
            {
              "label": "CHEST Journal - Aspiration Pneumonia (2024)",
              "url": "https://journal.chestnet.org/"
            }
          ]
        }
      }
    },
    {
      "id": "lung-abscess",
      "name": "Lung Abscess",
      "synonyms": [
        "lung abscess",
        "pulmonary abscess",
        "necrotizing pneumonia"
      ],
      "icd10": [
        "J85.2",
        "J85.1"
      ],
      "severity": [
        "severe"
      ],
      "shortDescription": "Necrotic cavity within the lung parenchyma containing purulent material, typically >2cm in diameter",
      "sections": {
        "overview": {
          "id": "overview",
          "title": "Overview & Clinical Presentation",
          "content": {
            "definition": "Lung abscess: necrotic cavity (>2cm) with air-fluid level on imaging, containing purulent material. Necrotizing pneumonia: multiple small (<2cm) abscesses within consolidated lung.",
            "clinical_presentation": "Subacute onset (weeks): fever, productive cough with foul-smelling/putrid sputum, weight loss, night sweats, pleuritic chest pain, hemoptysis. Chronic symptoms distinguish from acute pneumonia.",
            "risk_factors": [
              "Aspiration (alcoholism, seizures, stroke, dysphagia)",
              "POor oral hygiene OR periodontal disease",
              "Immunosuppression (HIV, steroids, chemotherapy)",
              "Bronchial obstruction (tumor, foreign body)",
              "Septic emboli (endocarditis, IV drug use)",
              "Necrotizing pneumonia (S. aureus, Klebsiella, Pseudomonas)"
            ],
            "complications": "Empyema, bronchopleural fistula, massive hemoptysis, septic emboli, brain abscess"
          },
          "references": []
        },
        "diagnostics": {
          "id": "diagnostics",
          "title": "Diagnostic Strategy & Tests",
          "content": {
            "essential_tests": [
              "Chest X-ray (thick-walled cavity with air-fluid level)",
              "CT chest with contrast (defines size, location, complications)",
              "Blood cultures (2 sets)",
              "CBC with differential",
              "Basic metabolic panel",
              "Sputum Gram stain and culture (if productive)"
            ],
            "conditional_tests": [
              "Bronchoscopy with BAL (if sputum non-diagnostic, rule out malignancy)",
              "CT-guided percutaneous aspiration (if bronchoscopy non-diagnostic)",
              "Anaerobic cultures (if putrid sputum)",
              "Fungal cultures (if immunocompromised)",
              "Echocardiography (rule out endocarditis if septic emboli suspected)"
            ],
            "imaging_features": "Chest X-ray: thick-walled cavity (>4mm) with air-fluid level, typically in dependent segments (posterior upper lobes, superior lower lobes). CT: better defines size, multilocularity, pleural involvement."
          },
          "references": []
        },
        "microbiology": {
          "id": "microbiology",
          "title": "Microbiology & Pathogens",
          "content": {
            "primary_lung_abscess": {
              "definition": "Aspiration-related, community-acquired",
              "pathogens": [
                "Anaerobes (60-80%): Peptostreptococcus, Prevotella, Bacteroides, Fusobacterium",
                "Streptococcus milleri group (S. anginosus, S. constellatus, S. intermedius)",
                "Staphylococcus aureus",
                "Klebsiella pneumoniae (alcoholics, diabetics)",
                "Mixed aerobic-anaerobic flora (common)"
              ]
            },
            "secondary_lung_abscess": {
              "definition": "POst-obstructive, hematogenous, OR healthcare-associated",
              "pathogens": [
                "Staphylococcus aureus (including MRSA) - post-influenza, IVDU",
                "Pseudomonas aeruginosa - healthcare-associated, bronchiectasis",
                "Klebsiella pneumoniae - alcoholics, diabetics",
                "Nocardia - immunocompromised",
                "Fungi (Aspergillus, Mucor) - immunocompromised"
              ]
            },
            "note": "Anaerobic cultures often negative due to fastidious organisms. Putrid sputum is pathognomonic for anaerobes."
          },
          "references": []
        },
        "empiric": {
          "id": "empiric",
          "title": "Empiric Antibiotic Therapy",
          "content": {
            "primary_lung_abscess": {
              "regimen": "Anaerobic coverage essential",
              "first_line": [
                "Ampicillin-sulbactam 3g IV q6h",
                "Piperacillin-tazobactam 4.5g IV q6h",
                "Clindamycin 600-900mg IV q8h + Ceftriaxone 2g IV q24h"
              ],
              "alternative": [
                "Meropenem 1g IV q8h (if severe OR failed initial therapy)",
                "Ertapenem 1g IV q24h (if ESBL risk)"
              ]
            },
            "secondary_lung_abscess": {
              "regimen": "Broader coverage for MRSA/Pseudomonas",
              "options": [
                "Vancomycin 15-20mg/kg IV q8-12h + Piperacillin-tazobactam 4.5g IV q6h",
                "Linezolid 600mg IV/PO q12h + Meropenem 1g IV q8h"
              ]
            },
            "immunocompromised": "Add antifungal coverage (voriconazole OR amphotericin B) if fungal abscess suspected. Consider Nocardia (TMP-SMX).",
            "note": "Metronidazole monotherapy is INADEQUATE (poor activity against aerobic streptococci). Always combine with beta-lactam OR use combination agent."
          },
          "references": []
        },
        "definitive": {
          "id": "definitive",
          "title": "Pathogen-Directed Therapy",
          "content": {
            "anaerobes": "Ampicillin-sulbactam 3g IV q6h OR Clindamycin 600-900mg IV q8h OR Metronidazole 500mg IV q8h (with beta-lactam)",
            "strep_milleri": "Penicillin G 2-4 MU IV q4h OR Ceftriaxone 2g IV q24h",
            "MRSA": "Vancomycin 15-20mg/kg IV q8-12h OR Linezolid 600mg IV/PO q12h",
            "klebsiella": "Ceftriaxone 2g IV q24h OR Meropenem 1g IV q8h (if ESBL)",
            "pseudomonas": "Piperacillin-tazobactam 4.5g IV q6h OR Cefepime 2g IV q8h OR Meropenem 1g IV q8h",
            "nocardia": "TMP-SMX 5mg/kg (TMP component) IV q6-8h for 6-12 months",
            "IV_to_po_switch": "Switch after clinical improvement (afebrile, decreasing cavity size on imaging): Amoxicillin-clavulanate 875mg PO q12h OR Clindamycin 450mg PO q6h"
          },
          "references": []
        },
        "duration": {
          "id": "duration",
          "title": "Treatment Duration",
          "content": {
            "standard_duration": "Prolonged therapy required: 3-4 weeks IV, then switch to PO for total 6-8 weeks",
            "extended_duration": "Large abscesses (>6cm), slow response, OR immunocompromised: 8-12 weeks total",
            "monitoring": "Serial chest X-rays every 2-4 weeks to document cavity resolution. CT chest if no improvement after 4-6 weeks.",
            "stopping_criteria": [
              "Clinical improvement (afebrile, resolution of symptoms)",
              "Radiographic improvement (decreasing cavity size, resolving air-fluid level)",
              "Normalization of inflammatory markers (WBC, CRP)",
              "Complete cavity resolution not required before stopping antibiotics"
            ],
            "note": "Radiographic resolution lags clinical improvement by weeks to months. Do not prolong antibiotics solely for persistent cavity if clinically improved."
          },
          "references": []
        },
        "special": {
          "id": "special",
          "title": "Special Populations & Procedures",
          "content": {
            "surgical_indications": [
              "Failure of medical therapy after 4-6 weeks",
              "Large abscess (>6cm) with poor drainage",
              "Massive hemoptysis",
              "Suspected malignancy OR foreign body",
              "Bronchopleural fistula OR empyema"
            ],
            "percutaneous_drainage": "Consider CT-guided drainage for large (>4-6cm) peripheral abscesses not responding to antibiotics. Contraindicated if high bleeding risk OR central location.",
            "bronchoscopy": "Therapeutic bronchoscopy for drainage rarely effective. Mainly diagnostic (rule out obstruction, obtain cultures).",
            "renal_impairment": "Adjust beta-lactam and vancomycin doses. Avoid aminoglycosides.",
            "pregnancy": "Preferred: Ampicillin-sulbactam OR Piperacillin-tazobactam. Avoid fluoroquinolones, metronidazole (1st trimester)."
          },
          "references": []
        },
        "stewardship": {
          "id": "stewardship",
          "title": "Antimicrobial Stewardship",
          "content": {
            "red_flags": [
              "Metronidazole monotherapy (inadequate for aerobic streptococci)",
              "Inadequate anaerobic coverage (e.g., ceftriaxone alone)",
              "Premature switch to PO before clinical stability",
              "Prolonged IV therapy beyond 3-4 weeks without clear indication",
              "Failure to obtain cultures before starting antibiotics"
            ],
            "key_stewardship_points": [
              "Always provide anaerobic coverage for primary lung abscess",
              "Prolonged therapy (6-8 weeks total) is necessary - do not stop prematurely",
              "Switch to PO after 3-4 weeks IV if clinically improving",
              "Radiographic resolution lags clinical improvement - do not over-treat",
              "Consider surgical consultation if no improvement after 4-6 weeks"
            ],
            "antibiotic_timeout": "Weekly review: Is patient improving clinically? Are cultures positive? Can we narrow spectrum? Is cavity size decreasing? Ready for IV-to-PO switch?"
          },
          "references": []
        },
        "references": {
          "id": "references",
          "title": "Clinical References",
          "content": {},
          "references": [
            {
              "label": "Johns Hopkins ABX Guide - Lung Abscess",
              "url": "https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_ABX_Guide/540131/all/Lung_Abscess"
            },
            {
              "label": "Sanford Guide to Antimicrobial Therapy (2025)",
              "url": "https://www.sanfordguide.com/"
            },
            {
              "label": "StatPearls - Lung Abscess (2024)",
              "url": "https://www.ncbi.nlm.nih.gov/books/NBK555920/"
            }
          ]
        }
      }
    },
    {
      "id": "acute-bronchitis",
      "name": "Acute Bronchitis",
      "synonyms": [
        "acute bronchitis",
        "chest cold",
        "acute cough illness"
      ],
      "icd10": [
        "J20.9",
        "J40"
      ],
      "severity": [
        "mild"
      ],
      "shortDescription": "Self-limited inflammation of the bronchi, typically viral, presenting with acute cough lasting <3 weeks",
      "sections": {
        "overview": {
          "id": "overview",
          "title": "Overview & Clinical Presentation",
          "content": {
            "definition": "Acute bronchitis: self-limited inflammation of the large airways (bronchi) causing acute cough, typically lasting 1-3 weeks. Predominantly viral etiology (>90%).",
            "clinical_presentation": "Acute cough (productive OR non-productive) lasting <3 weeks, with OR without sputum production. May have low-grade fever, wheezing, chest discomfort. NO signs of pneumonia (no focal consolidation, no hypoxemia).",
            "key_distinction": "Acute bronchitis vs pneumonia: Bronchitis has NO focal consolidation on chest X-ray, NO hypoxemia, NO tachypnea, NO high fever (>38.5°C). If these present, consider pneumonia.",
            "viral_etiology": [
              "Rhinovirus (most common)",
              "Coronavirus (including SARS-CoV-2)",
              "Influenza A and B",
              "Respiratory syncytial virus (RSV)",
              "Adenovirus",
              "Parainfluenza"
            ],
            "bacterial_etiology": "Rare (<10%): Bordetella pertussis (whooping cough), Mycoplasma pneumoniae, Chlamydia pneumoniae"
          },
          "references": []
        },
        "diagnostics": {
          "id": "diagnostics",
          "title": "Diagnostic Strategy & Tests",
          "content": {
            "clinical_diagnosis": "Acute bronchitis is a CLINICAL diagnosis. Routine testing is NOT recommended for uncomplicated cases.",
            "when_not_to_test": [
              "No chest X-ray needed if: age <65, HR <100, RR <24, temp <38°C, no focal consolidation on exam",
              "No sputum culture (not helpful - often colonization)",
              "No procalcitonin (not validated for acute bronchitis)",
              "No routine viral testing (does not change management)"
            ],
            "when_to_test": [
              "Chest X-ray: if pneumonia suspected (focal findings, hypoxemia, high fever, tachypnea)",
              "Influenza testing: if influenza season and <48h symptom onset (antiviral eligible)",
              "Pertussis testing (PCR OR culture): if paroxysmal cough, post-tussive emesis, inspiratory whoop, OR exposure",
              "COVID-19 testing: if compatible symptoms and local prevalence"
            ],
            "diagnostic_stewardship": "Avoid unnecessary testing. Chest X-ray and labs do NOT reduce antibiotic prescribing and increase costs."
          },
          "references": []
        },
        "microbiology": {
          "id": "microbiology",
          "title": "Microbiology & Pathogens",
          "content": {
            "viral_predominance": "Viruses cause >90% of acute bronchitis cases. Bacterial superinfection is rare.",
            "color_of_sputum_myth": "Purulent (green/yellow) sputum does NOT indicate bacterial infection. Sputum color is due to neutrophil peroxidase, not bacteria. Do NOT use sputum color to guide antibiotic prescribing.",
            "pertussis": "Bordetella pertussis: paroxysmal cough lasting >2 weeks, post-tussive emesis, inspiratory whoop. More common in adolescents/adults with waning immunity.",
            "atypical_bacteria": "Mycoplasma pneumoniae and Chlamydia pneumoniae: cause prolonged cough (>3 weeks) but rarely require treatment in immunocompetent adults."
          },
          "references": []
        },
        "empiric": {
          "id": "empiric",
          "title": "Treatment Approach",
          "content": {
            "antibiotics_not_recommended": "Antibiotics are NOT recommended for routine acute bronchitis in healthy adults. No benefit in symptom duration OR severity. Increases adverse effects and antibiotic resistance.",
            "symptomatic_treatment": [
              "Cough suppressants: Dextromethorphan 10-20mg PO q4-6h PRN",
              "Expectorants: Guaifenesin 200-400mg PO q4h PRN",
              "NSAIDs: Ibuprofen 400mg PO q6-8h OR Acetaminophen 500-1000mg PO q6h PRN",
              "Honey: 1-2 teaspoons for cough (evidence-based, especially in children >1 year)",
              "Hydration and rest"
            ],
            "when_to_consider_antibiotics": {
              "pertussis_confirmed": "Azithromycin 500mg PO day 1, then 250mg PO days 2-5 (OR 500mg PO daily x3 days)",
              "pertussis_suspected": "Treat if <3 weeks of symptoms (reduces transmission) OR high-risk contacts (infants, pregnant women)",
              "copd_exacerbation": "See AECOPD module - antibiotics indicated if increased dyspnea + increased sputum purulence + increased sputum volume"
            },
            "influenza": "Oseltamivir 75mg PO q12h x5 days if <48h symptom onset and high-risk patient OR severe illness"
          },
          "references": []
        },
        "definitive": {
          "id": "definitive",
          "title": "Pathogen-Specific Therapy",
          "content": {
            "pertussis": {
              "first_line": "Azithromycin 500mg PO day 1, then 250mg PO days 2-5 (total 5 days)",
              "alternatives": [
                "Clarithromycin 500mg PO q12h x7 days",
                "TMP-SMX DS 1 tab PO q12h x14 days (if macrolide allergy)"
              ],
              "note": "Antibiotics do NOT improve symptoms if >3 weeks of cough. Treat to reduce transmission."
            },
            "mycoplasma_chlamydia": {
              "indication": "Only if prolonged symptoms (>3 weeks) and high suspicion",
              "options": [
                "Azithromycin 500mg PO day 1, then 250mg PO days 2-5",
                "Doxycycline 100mg PO q12h x7-10 days"
              ]
            },
            "viral": "Supportive care only. Antibiotics NOT indicated."
          },
          "references": []
        },
        "duration": {
          "id": "duration",
          "title": "Expected Course & Duration",
          "content": {
            "natural_history": "Acute cough typically lasts 1-3 weeks. 50% of patients still coughing at 2 weeks, 25% at 3 weeks. This is NORMAL and does NOT indicate bacterial infection.",
            "when_to_reassess": "Reassess if: cough persists >3 weeks, worsening symptoms, new fever, dyspnea, hemoptysis, OR weight loss. Consider alternative diagnoses (pneumonia, pertussis, asthma, GERD, post-nasal drip).",
            "antibiotic_duration_if_indicated": {
              "pertussis": "5 days (azithromycin) OR 7-14 days (clarithromycin, TMP-SMX)",
              "mycoplasma_chlamydia": "5-10 days"
            }
          },
          "references": []
        },
        "special": {
          "id": "special",
          "title": "Special Populations",
          "content": {
            "copd_patients": "Acute bronchitis in COPD patients may represent AECOPD. See AECOPD module for antibiotic indications (Anthonisen criteria).",
            "immunocompromised": "Lower threshold for chest X-ray and antibiotics. Consider atypical pathogens (fungi, PCP).",
            "pregnancy": "Symptomatic treatment preferred. If antibiotics needed: Azithromycin OR Amoxicillin. Avoid doxycycline, fluoroquinolones.",
            "elderly": "Higher risk of pneumonia. Lower threshold for chest X-ray if fever, tachypnea, OR hypoxemia.",
            "pertussis_contacts": "POst-exposure prophylaxis: Azithromycin 500mg PO day 1, then 250mg PO days 2-5 for close contacts (especially infants, pregnant women)."
          },
          "references": []
        },
        "stewardship": {
          "id": "stewardship",
          "title": "Antimicrobial Stewardship",
          "content": {
            "red_flags": [
              "Prescribing antibiotics for uncomplicated acute bronchitis (viral illness)",
              "Using sputum color (green/yellow) to justify antibiotics",
              "Ordering chest X-ray OR labs for low-risk patients (increases antibiotic prescribing)",
              "Prescribing fluoroquinolones OR broad-spectrum antibiotics for acute bronchitis"
            ],
            "key_stewardship_messages": [
              "Acute bronchitis is viral in >90% of cases - antibiotics NOT indicated",
              "Purulent sputum does NOT mean bacterial infection",
              "Cough lasting 1-3 weeks is NORMAL for acute bronchitis",
              "Patient education is key: 'Antibiotics will not help your cough and may cause harm'",
              "Offer symptomatic treatment (cough suppressants, NSAIDs, honey)"
            ],
            "patient_education": "Explain: 'Your cough is caused by a virus. Antibiotics do not work against viruses and will not make you feel better faster. They can cause side effects like diarrhea and allergic reactions. Your cough should improve in 1-3 weeks with rest and symptomatic treatment.'",
            "delayed_prescribing": "Consider delayed antibiotic prescription strategy: 'Fill this prescription only if your symptoms worsen OR do not improve after 7 days.' Reduces antibiotic use by 30-40%."
          },
          "references": []
        },
        "references": {
          "id": "references",
          "title": "Clinical References",
          "content": {},
          "references": [
            {
              "label": "CDC - Acute Bronchitis Guidelines",
              "url": "https://www.CDC.gov/antibiotic-use/bronchitis.html"
            },
            {
              "label": "ACCP Acute Bronchitis Guidelines",
              "url": "https://journal.chestnet.org/"
            },
            {
              "label": "StatPearls - Acute Bronchitis (2024)",
              "url": "https://www.ncbi.nlm.nih.gov/books/NBK448067/"
            }
          ]
        }
      }
    },
    {
      "id": "AECOPD",
      "name": "Acute Exacerbation of COPD (AECOPD)",
      "synonyms": [
        "AECOPD",
        "COPD exacerbation",
        "acute bronchitis in COPD"
      ],
      "icd10": [
        "J44.0",
        "J44.1"
      ],
      "severity": [
        "mild",
        "moderate",
        "severe"
      ],
      "shortDescription": "Acute worsening of respiratory symptoms in COPD patients beyond normal day-to-day variation, requiring change in medication",
      "sections": {
        "overview": {
          "id": "overview",
          "title": "Overview & Clinical Presentation",
          "content": {
            "definition": "AECOPD: acute worsening of respiratory symptoms (dyspnea, cough, sputum production/purulence) beyond normal day-to-day variation, requiring change in regular medication.",
            "clinical_presentation": "Increased dyspnea, increased sputum volume, increased sputum purulence (Anthonisen criteria). May have fever, wheezing, chest tightness, fatigue.",
            "anthonisen_criteria": {
              "type_1_severe": "All 3 cardinal symptoms: increased dyspnea + increased sputum volume + increased sputum purulence",
              "type_2_moderate": "2 of 3 cardinal symptoms",
              "type_3_mild": "1 cardinal symptom + ≥1 of: URTI in past 5 days, fever, increased wheezing, increased cough, increased HR/RR"
            },
            "triggers": [
              "Viral infections (50-70%): rhinovirus, influenza, RSV, coronavirus",
              "Bacterial infections (40-50%): H. influenzae, S. pneumoniae, M. catarrhalis, P. aeruginosa",
              "Environmental: air pollution, temperature changes",
              "Non-infectious: heart failure, pulmonary embolism, pneumothorax, medication non-adherence"
            ]
          },
          "references": []
        },
        "diagnostics": {
          "id": "diagnostics",
          "title": "Diagnostic Strategy & Tests",
          "content": {
            "clinical_diagnosis": "AECOPD is primarily a clinical diagnosis based on symptom worsening.",
            "essential_tests": [
              "Pulse oximetry OR ABG (assess hypoxemia, hypercapnia)",
              "Chest X-ray (rule out pneumonia, pneumothorax, heart failure)",
              "ECG (rule out cardiac ischemia, arrhythmia)",
              "CBC (leukocytosis suggests bacterial infection)"
            ],
            "conditional_tests": [
              "Sputum Gram stain and culture (if purulent sputum, frequent exacerbations, OR ICU admission)",
              "Blood cultures (if febrile OR septic)",
              "BNP OR pro-BNP (if heart failure suspected)",
              "D-dimer and CT angiography (if PE suspected)",
              "Respiratory viral panel (influenza season)"
            ],
            "severity_assessment": {
              "mild": "Increased symptoms, no respiratory failure, outpatient management",
              "moderate": "Increased symptoms, no respiratory failure, hospitalization needed",
              "severe": "Respiratory failure (hypoxemia, hypercapnia, acidosis) OR ICU admission"
            }
          },
          "references": []
        },
        "microbiology": {
          "id": "microbiology",
          "title": "Microbiology & Pathogens",
          "content": {
            "bacterial_pathogens": [
              "Haemophilus influenzae (30-40%)",
              "Streptococcus pneumoniae (10-15%)",
              "Moraxella catarrhalis (10-15%)",
              "Pseudomonas aeruginosa (5-10% - risk factors: severe COPD, frequent exacerbations, recent antibiotics, bronchiectasis)"
            ],
            "viral_pathogens": [
              "Rhinovirus (most common)",
              "Influenza A and B",
              "Respiratory syncytial virus (RSV)",
              "Coronavirus (including SARS-CoV-2)",
              "Parainfluenza"
            ],
            "pseudomonas_risk_factors": [
              "FEV1 <50% predicted",
              "≥4 exacerbations per year",
              "Recent hospitalization OR antibiotics",
              "Chronic oral corticosteroids",
              "Bronchiectasis"
            ]
          },
          "references": []
        },
        "empiric": {
          "id": "empiric",
          "title": "Antibiotic Therapy Indications",
          "content": {
            "when_to_use_antibiotics": {
              "indicated": "Anthonisen Type 1 (all 3 symptoms) OR Type 2 (2 of 3 symptoms) exacerbations",
              "also_indicated": "Severe exacerbation requiring mechanical ventilation (invasive OR non-invasive)",
              "not_indicated": "Anthonisen Type 3 (1 symptom) exacerbations - treat with bronchodilators and corticosteroids only"
            },
            "outpatient_mild_moderate": {
              "no_pseudomonas_risk": [
                "Amoxicillin-clavulanate 875mg PO q12h x5 days",
                "Azithromycin 500mg PO day 1, then 250mg PO days 2-5",
                "Doxycycline 100mg PO q12h x5 days",
                "Cefuroxime 500mg PO q12h x5 days"
              ],
              "pseudomonas_risk": [
                "Levofloxacin 750mg PO q24h x5 days",
                "Ciprofloxacin 500-750mg PO q12h x5 days"
              ]
            },
            "inpatient_severe": {
              "no_pseudomonas_risk": [
                "Ceftriaxone 1-2g IV q24h",
                "Ampicillin-sulbactam 3g IV q6h",
                "Levofloxacin 750mg IV q24h"
              ],
              "pseudomonas_risk": [
                "Piperacillin-tazobactam 4.5g IV q6h",
                "Cefepime 2g IV q8h",
                "Meropenem 1g IV q8h (if prior carbapenem-resistant organism)"
              ]
            },
            "duration": "5 days for most patients (non-inferior to 7-14 days). Extend to 7 days if slow response OR Pseudomonas."
          },
          "references": []
        },
        "definitive": {
          "id": "definitive",
          "title": "Pathogen-Directed Therapy",
          "content": {
            "h_influenzae": "Amoxicillin-clavulanate 875mg PO q12h OR Ceftriaxone 1g IV q24h",
            "s_pneumoniae": "Amoxicillin 1g PO q8h OR Ceftriaxone 1g IV q24h",
            "m_catarrhalis": "Amoxicillin-clavulanate 875mg PO q12h OR Azithromycin 500mg PO q24h",
            "pseudomonas": "Ciprofloxacin 500-750mg PO q12h OR Piperacillin-tazobactam 4.5g IV q6h OR Cefepime 2g IV q8h",
            "de_escalation": "Narrow spectrum based on culture results. Switch to PO when clinically stable.",
            "note": "Most AECOPD are viral OR non-infectious. Do not prolong antibiotics beyond 5 days without clear indication."
          },
          "references": []
        },
        "duration": {
          "id": "duration",
          "title": "Treatment Duration",
          "content": {
            "antibiotic_duration": "5 days for most AECOPD (non-inferior to longer courses)",
            "extended_duration": "7 days if: Pseudomonas infection, slow clinical response, severe exacerbation requiring ICU",
            "corticosteroid_duration": "Prednisone 40mg PO daily x5 days (equivalent to longer courses with fewer side effects)",
            "stopping_criteria": [
              "Improved dyspnea and sputum production",
              "Return to baseline respiratory status",
              "No fever",
              "Stable oxygen saturation"
            ],
            "note": "Longer antibiotic courses (>7 days) do NOT improve outcomes and increase adverse effects and resistance."
          },
          "references": []
        },
        "special": {
          "id": "special",
          "title": "Adjunctive Therapy & Prevention",
          "content": {
            "bronchodilators": {
              "saba": "Albuterol 2.5-5mg nebulized q4-6h OR 2-4 puffs MDI q4-6h",
              "sama": "Ipratropium 0.5mg nebulized q6h OR 2-4 puffs MDI q6h",
              "combination": "Albuterol-ipratropium nebulized q4-6h (more effective than either alone)"
            },
            "corticosteroids": {
              "indication": "All hospitalized AECOPD patients",
              "regimen": "Prednisone 40mg PO daily x5 days OR Methylprednisolone 125mg IV q6h x72h then taper",
              "note": "Longer courses (>5-7 days) increase adverse effects without additional benefit"
            },
            "oxygen_therapy": "Target SpO2 88-92% (avoid hyperoxia - risk of CO2 retention)",
            "ventilatory_support": {
              "niv": "Non-invasive ventilation (BiPAP) for: pH 7.25-7.35, PaCO2 >45 mmHg, RR >25",
              "invasive": "Intubation for: pH <7.25, severe hypoxemia, altered mental status, respiratory arrest"
            },
            "prevention": [
              "Smoking cessation (most important)",
              "Influenza vaccine (annual)",
              "Pneumococcal vaccine (PCV20 OR PCV15 + PPSV23)",
              "COVID-19 vaccine",
              "Inhaled corticosteroids + LABA for frequent exacerbators (≥2 per year)",
              "Pulmonary rehabilitation"
            ]
          },
          "references": []
        },
        "stewardship": {
          "id": "stewardship",
          "title": "Antimicrobial Stewardship",
          "content": {
            "red_flags": [
              "Prescribing antibiotics for Anthonisen Type 3 exacerbations (1 symptom only)",
              "Using fluoroquinolones as first-line without Pseudomonas risk factors",
              "Antibiotic duration >5-7 days without clear indication",
              "Failure to use corticosteroids (more important than antibiotics for AECOPD)",
              "Using sputum color alone to justify antibiotics"
            ],
            "key_stewardship_points": [
              "Not all AECOPD require antibiotics - use Anthonisen criteria",
              "5 days of antibiotics is sufficient for most patients",
              "Corticosteroids are MORE important than antibiotics for AECOPD",
              "Avoid fluoroquinolones unless Pseudomonas risk factors present",
              "Sputum purulence alone does NOT indicate bacterial infection"
            ],
            "antibiotic_timeout": "48-72h review: Is patient improving? Are cultures positive? Can we stop antibiotics at day 5? Are corticosteroids being used appropriately?"
          },
          "references": []
        },
        "references": {
          "id": "references",
          "title": "Clinical References",
          "content": {},
          "references": [
            {
              "label": "GOLD COPD Guidelines (2025)",
              "url": "https://goldcopd.org/2025-gold-report/"
            },
            {
              "label": "ATS/ERS COPD Exacerbation Guidelines",
              "url": "https://www.thoracic.org/statements/"
            },
            {
              "label": "Sanford Guide to Antimicrobial Therapy (2025)",
              "url": "https://www.sanfordguide.com/"
            }
          ]
        }
      }
    },
    {
      "id": "bronchiectasis",
      "name": "Bronchiectasis with Acute Infection",
      "synonyms": [
        "bronchiectasis",
        "bronchiectasis exacerbation",
        "infected bronchiectasis"
      ],
      "icd10": [
        "J47.0",
        "J47.1",
        "J47.9"
      ],
      "severity": [
        "moderate",
        "severe"
      ],
      "shortDescription": "Permanent dilation of bronchi with recurrent infections, characterized by chronic productive cough and frequent exacerbations",
      "sections": {
        "overview": {
          "id": "overview",
          "title": "Overview & Clinical Presentation",
          "content": {
            "definition": "Bronchiectasis: permanent, abnormal dilation of bronchi due to chronic inflammation and infection. Characterized by chronic productive cough, recurrent respiratory infections, and progressive lung damage.",
            "clinical_presentation": "Chronic daily productive cough with purulent sputum, recurrent respiratory infections, dyspnea, hemoptysis, fatigue, weight loss. Acute exacerbation: increased sputum volume/purulence, worsening dyspnea, fever.",
            "etiology": [
              "POst-infectious (TB, severe pneumonia, pertussis)",
              "Cystic fibrosis (most common in children)",
              "Immunodeficiency (CVID, HIV, hypogammaglobulinemia)",
              "Allergic bronchopulmonary aspergillosis (ABPA)",
              "Primary ciliary dyskinesia",
              "Connective tissue disease (RA, Sjögren's)",
              "Idiopathic (40-50% of cases)"
            ],
            "exacerbation_criteria": "≥3 of: increased sputum volume, increased sputum purulence, increased dyspnea, increased cough, fever, malaise, reduced lung function, radiographic changes"
          },
          "references": []
        },
        "diagnostics": {
          "id": "diagnostics",
          "title": "Diagnostic Strategy & Tests",
          "content": {
            "essential_tests": [
              "High-resolution CT chest (gold standard for diagnosis - shows bronchial dilation, signet ring sign)",
              "Sputum Gram stain and culture (essential for pathogen identification)",
              "Pulse oximetry OR ABG",
              "CBC with differential",
              "Basic metabolic panel"
            ],
            "conditional_tests": [
              "Pulmonary function tests (assess severity, obstruction)",
              "Immunoglobulin levels (IgG, IgA, IgM, IgE) - rule out immunodeficiency",
              "Aspergillus IgE and precipitins (rule out ABPA)",
              "Sweat chloride test (rule out CF in young patients)",
              "Alpha-1 antitrypsin level",
              "Rheumatoid factor, ANA (rule out connective tissue disease)",
              "Mycobacterial cultures (if endemic area OR risk factors)"
            ],
            "severity_assessment": "Bronchiectasis Severity Index (BSI) OR FACED score to predict exacerbations and mortality"
          },
          "references": []
        },
        "microbiology": {
          "id": "microbiology",
          "title": "Microbiology & Pathogens",
          "content": {
            "common_pathogens": [
              "Haemophilus influenzae (40-50% - most common)",
              "Pseudomonas aeruginosa (20-30% - associated with worse outcomes)",
              "Moraxella catarrhalis (10-15%)",
              "Streptococcus pneumoniae (10-15%)",
              "Staphylococcus aureus (including MRSA) (5-10%)"
            ],
            "chronic_colonization": "Pseudomonas aeruginosa chronic colonization (≥2 positive cultures ≥3 months apart) associated with: more frequent exacerbations, accelerated lung function decline, increased mortality",
            "nontuberculous_mycobacteria": "NTM (M. avium complex, M. abscessus) in 10-20% of bronchiectasis patients. Suspect if: refractory symptoms, cavitary disease, nodular infiltrates. Requires prolonged multi-drug therapy.",
            "aspergillus": "Aspergillus fumigatus colonization common. ABPA if: elevated IgE, eosinophilia, positive Aspergillus IgE/precipitins, central bronchiectasis."
          },
          "references": []
        },
        "empiric": {
          "id": "empiric",
          "title": "Antibiotic Therapy for Exacerbations",
          "content": {
            "mild_exacerbation_outpatient": {
              "no_pseudomonas": [
                "Amoxicillin-clavulanate 875mg PO q12h x14 days",
                "Azithromycin 500mg PO day 1, then 250mg PO days 2-14",
                "Doxycycline 100mg PO q12h x14 days"
              ],
              "pseudomonas_colonized": [
                "Ciprofloxacin 500-750mg PO q12h x14 days",
                "Levofloxacin 750mg PO q24h x14 days"
              ]
            },
            "severe_exacerbation_inpatient": {
              "no_pseudomonas": [
                "Ceftriaxone 2g IV q24h",
                "Ampicillin-sulbactam 3g IV q6h",
                "Piperacillin-tazobactam 4.5g IV q6h"
              ],
              "pseudomonas_colonized": [
                "Piperacillin-tazobactam 4.5g IV q6h",
                "Cefepime 2g IV q8h",
                "Meropenem 1g IV q8h (if MDR Pseudomonas)",
                "Consider dual anti-pseudomonal therapy: beta-lactam + aminoglycoside OR fluoroquinolone"
              ]
            },
            "duration": "14 days for most exacerbations (longer than CAP/AECOPD due to impaired clearance). Extend to 21 days if Pseudomonas OR slow response.",
            "note": "Always obtain sputum culture before starting antibiotics. Tailor therapy based on prior culture results and local resistance patterns."
          },
          "references": []
        },
        "definitive": {
          "id": "definitive",
          "title": "Pathogen-Directed Therapy",
          "content": {
            "h_influenzae": "Amoxicillin-clavulanate 875mg PO q12h OR Ceftriaxone 2g IV q24h",
            "pseudomonas": {
              "oral": "Ciprofloxacin 750mg PO q12h x14-21 days",
              "IV": "Piperacillin-tazobactam 4.5g IV q6h OR Cefepime 2g IV q8h OR Meropenem 1g IV q8h",
              "dual_therapy": "Consider for severe infection OR MDR: beta-lactam + aminoglycoside (tobramycin 5-7mg/kg IV q24h) OR + ciprofloxacin"
            },
            "MRSA": "Vancomycin 15-20mg/kg IV q8-12h OR Linezolid 600mg IV/PO q12h",
            "s_pneumoniae": "Amoxicillin 1g PO q8h OR Ceftriaxone 2g IV q24h",
            "m_catarrhalis": "Amoxicillin-clavulanate 875mg PO q12h OR Azithromycin 500mg PO q24h",
            "ntm": "Consult infectious disease specialist. Typically: Azithromycin + Ethambutol + Rifampin for M. avium complex (12-18 months)"
          },
          "references": []
        },
        "duration": {
          "id": "duration",
          "title": "Treatment Duration & Monitoring",
          "content": {
            "acute_exacerbation": "14 days for most pathogens. Extend to 21 days for Pseudomonas OR slow clinical response.",
            "chronic_suppressive_therapy": {
              "indication": "≥3 exacerbations per year requiring antibiotics",
              "options": [
                "Azithromycin 250-500mg PO 3x/week (reduces exacerbations by 40-50%)",
                "Inhaled tobramycin 300mg nebulized q12h (28 days on, 28 days off) for Pseudomonas",
                "Inhaled colistin 1-2 MU nebulized q12h for MDR Pseudomonas"
              ],
              "monitoring": "Baseline and periodic: audiometry (azithromycin), renal function (aminoglycosides), sputum cultures, ECG (QTc prolongation)"
            },
            "stopping_criteria": [
              "Return to baseline sputum volume and purulence",
              "Improved dyspnea and cough",
              "No fever",
              "Stable OR improved lung function"
            ]
          },
          "references": []
        },
        "special": {
          "id": "special",
          "title": "Airway Clearance & Prevention",
          "content": {
            "airway_clearance": {
              "essential": "Daily airway clearance is cornerstone of bronchiectasis management",
              "techniques": [
                "Chest physiotherapy (postural drainage, percussion)",
                "POsitive expiratory pressure (PEP) devices",
                "High-frequency chest wall oscillation vests",
                "Autogenic drainage"
              ],
              "mucolytics": [
                "Hypertonic saline 7% nebulized q12h (improves mucus clearance)",
                "Dornase alfa (DNase) - only for CF-related bronchiectasis"
              ]
            },
            "prevention_strategies": [
              "Daily airway clearance (most important)",
              "Influenza vaccine (annual)",
              "Pneumococcal vaccine (PCV20 OR PCV15 + PPSV23)",
              "COVID-19 vaccine",
              "Avoid smoking and secondhand smoke",
              "Treat underlying cause (immunodeficiency, ABPA, GERD)"
            ],
            "surgical_indications": "Localized disease with recurrent infections OR massive hemoptysis refractory to medical therapy. Lung transplant for end-stage disease."
          },
          "references": []
        },
        "stewardship": {
          "id": "stewardship",
          "title": "Antimicrobial Stewardship",
          "content": {
            "red_flags": [
              "Treating chronic colonization (positive culture without symptoms) - NOT indicated",
              "Inadequate treatment duration (<14 days) for acute exacerbations",
              "Failure to obtain sputum cultures before starting antibiotics",
              "Empiric anti-pseudomonal therapy without prior Pseudomonas colonization",
              "Long-term suppressive antibiotics without clear indication (≥3 exacerbations/year)"
            ],
            "key_stewardship_points": [
              "Chronic colonization does NOT require treatment - only treat symptomatic exacerbations",
              "Always obtain sputum culture to guide therapy",
              "14-day duration is standard (longer than CAP/AECOPD)",
              "Reserve fluoroquinolones for Pseudomonas-colonized patients",
              "Airway clearance is MORE important than antibiotics for long-term management"
            ],
            "chronic_suppressive_therapy_criteria": "Only use if ≥3 exacerbations per year despite optimal airway clearance. Monitor for resistance and adverse effects.",
            "antibiotic_timeout": "Weekly review: Is patient improving? Are cultures back? Can we narrow spectrum? Is duration appropriate (14 days)? Is airway clearance optimized?"
          },
          "references": []
        },
        "references": {
          "id": "references",
          "title": "Clinical References",
          "content": {},
          "references": [
            {
              "label": "ERS Bronchiectasis Guidelines (2025)",
              "url": "https://erj.ersjournals.com/"
            },
            {
              "label": "BTS Bronchiectasis Guidelines",
              "url": "https://www.brit-thoracic.org.uk/quality-improvement/guidelines/bronchiectasis/"
            },
            {
              "label": "Sanford Guide to Antimicrobial Therapy (2025)",
              "url": "https://www.sanfordguide.com/"
            }
          ]
        }
      }
    }
  ],
  "common_respiratory_pathogens": {
    "streptococcus_pneumoniae": {
      "epidemiology": "Most common bacterial cause of CAP (30-40%). Incidence decreased with PCV13/PCV20 vaccination.",
      "clinical_clues": "Rust-colored sputum, lobar consolidation on CXR, bacteremia in 20-30% of hospitalized patients",
      "resistance": "Penicillin resistance 30-40% (but cephalosporins still effective for pneumonia). Macrolide resistance 20-40%.",
      "treatment": "Penicillin-susceptible: Penicillin G OR Amoxicillin. Penicillin-resistant: Ceftriaxone OR Levofloxacin.",
      "prevention": "PCV20 (single dose) OR PCV15 + PPSV23 (1 year apart) for adults ≥65 years OR immunocompromised",
      "note": "Penicillin MIC ≤2 mcg/mL is still treatable with high-dose penicillin OR ceftriaxone for pneumonia"
    },
    "haemophilus_influenzae": {
      "epidemiology": "10-20% of CAP, more common in COPD patients and smokers",
      "clinical_clues": "Purulent sputum, COPD exacerbation, chronic bronchitis, non-typeable strains most common",
      "resistance": "30-40% produce beta-lactamase (resistant to ampicillin)",
      "treatment": "Beta-lactamase negative: Ampicillin. Beta-lactamase positive: Amoxicillin-clavulanate OR Ceftriaxone.",
      "prevention": "Hib vaccine (children), smoking cessation, COPD management",
      "note": "Non-typeable H. influenzae (NTHi) not covered by Hib vaccine - common in COPD exacerbations"
    },
    "legionella_pneumophila": {
      "epidemiology": "2-8% of CAP, higher in outbreaks (water systems, cooling towers, travel)",
      "clinical_clues": "Hyponatremia, elevated LFTS, diarrhea, relative bradycardia, travel/water exposure history",
      "resistance": "Rare - fluoroquinolones and macrolides remain highly effective",
      "treatment": "Levofloxacin 750mg q24h (preferred for severe) OR Azithromycin 500mg q24h",
      "prevention": "Water system maintenance, avoid hot tubs/whirlpools in immunocompromised",
      "note": "Urinary antigen test detects only L. pneumophila serogroup 1 (70% of cases) - negative test does not rule out"
    },
    "mrsa_methicillin_resistant_staph_aureus": {
      "epidemiology": "10-20% of S. aureus isolates, declining in many regions. Risk factors: IVDU, recent hospitalization, hemodialysis",
      "clinical_clues": "Necrotizing pneumonia, cavitation, empyema, post-influenza pneumonia, IVDU",
      "resistance": "Resistant to all beta-lactams except ceftaroline. Vancomycin MIC creep (MIC 1.5-2) associated with treatment failure.",
      "treatment": "Vancomycin 15-20mg/kg q8-12h (target trough 15-20) OR Linezolid 600mg q12h (better lung penetration)",
      "prevention": "Contact precautions, decolonization (mupirocin nasal + chlorhexidine baths) for recurrent infections",
      "note": "MRSA nasal PCR negative has 95% NPV for MRSA pneumonia - can stop empiric coverage if negative"
    },
    "pseudomonas_aeruginosa": {
      "epidemiology": "20-30% of HAP/VAP, rare in CAP except in bronchiectasis/COPD with prior colonization",
      "clinical_clues": "Structural lung disease (bronchiectasis, COPD), prior antibiotics, healthcare exposure, green sputum",
      "resistance": "20-30% resistant to cefepime/piperacillin-tazobactam. Carbapenem resistance 10-20%. XDR strains emerging.",
      "treatment": "Cefepime 2g q8h OR Piperacillin-tazobactam 4.5g q6h OR Meropenem 1g q8h (based on susceptibility)",
      "prevention": "Avoid unnecessary antibiotics, optimize airway clearance in bronchiectasis",
      "note": "Double coverage (beta-lactam + aminoglycoside/fluoroquinolone) does NOT improve outcomes - use monotherapy once susceptible"
    },
    "klebsiella_pneumoniae": {
      "epidemiology": "10-20% of HAP/VAP, classic 'currant jelly' sputum in alcoholics (rare now)",
      "clinical_clues": "Healthcare exposure, diabetes, alcoholism, upper lobe cavitation (rare)",
      "resistance": "ESBL production 20-40% in healthcare settings. Carbapenem resistance (KPC) 5-20% in endemic areas.",
      "treatment": "ESBL: Meropenem OR Ertapenem. CRE: Ceftazidime-avibactam OR Meropenem-vaborbactam.",
      "prevention": "Contact precautions for CRE, hand hygiene, antibiotic stewardship",
      "note": "Avoid cephalosporins and piperacillin-tazobactam for ESBL even if susceptible in vitro (inoculum effect)"
    },
    "mycoplasma_pneumoniae": {
      "epidemiology": "10-20% of CAP, more common in younger patients (<40 years), outbreaks in closed communities",
      "clinical_clues": "Gradual onset, dry cough, extrapulmonary manifestations (rash, hemolytic anemia, myocarditis)",
      "resistance": "Macrolide resistance increasing (10-30% in some regions, especially Asia)",
      "treatment": "Azithromycin 500mg x1, then 250mg q24h OR Doxycycline 100mg q12h OR Levofloxacin 750mg q24h",
      "prevention": "None available (no vaccine)",
      "note": "Atypical pathogen - not visible on Gram stain, no cell wall (beta-lactams ineffective)"
    },
    "anaerobes_oral_flora": {
      "epidemiology": "Historically thought common in aspiration pneumonia, but rarely isolated in modern studies",
      "clinical_clues": "Foul-smelling sputum, lung abscess, empyema, necrotizing pneumonia, poor dentition",
      "resistance": "Bacteroides fragilis: 20-40% resistant to clindamycin",
      "treatment": "Ampicillin-sulbactam 3g q6h OR Piperacillin-tazobactam 4.5g q6h OR Clindamycin 600-900mg q8h",
      "prevention": "Oral hygiene, treat periodontal disease",
      "note": "Routine anaerobic coverage NOT recommended for aspiration pneumonia - only for lung abscess OR empyema"
    }
  }
}